Last reviewed · How we verify
GSK malaria vaccine 257049 Vaccine — Competitive Intelligence Brief
phase 2
Infectious Diseases
Biologic
Live · refreshed every 30 min
Target snapshot
GSK malaria vaccine 257049 Vaccine (GSK malaria vaccine 257049 Vaccine) — GlaxoSmithKline. This vaccine induces an immune response against Plasmodium falciparum, the parasite responsible for malaria.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK malaria vaccine 257049 Vaccine TARGET | GSK malaria vaccine 257049 Vaccine | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK malaria vaccine 257049 Vaccine CI watch — RSS
- GSK malaria vaccine 257049 Vaccine CI watch — Atom
- GSK malaria vaccine 257049 Vaccine CI watch — JSON
- GSK malaria vaccine 257049 Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). GSK malaria vaccine 257049 Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk-malaria-vaccine-257049-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab